Using artificial intelligence to evaluate pulmonary hypertension
Artificial Intelligence-Assisted Evaluation of Pulmonary Hypertension
Chinese Pulmonary Vascular Disease Research Group · NCT05566002
This study is testing if using artificial intelligence with different medical tests can help doctors find pulmonary hypertension earlier and more accurately in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese Pulmonary Vascular Disease Research Group (other) |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05566002 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients with pulmonary hypertension (PH) who undergo right heart catheterization at Fuwai Hospital. It aims to combine various clinical data, including results from chest X-rays, electrocardiograms, and echocardiograms, with artificial intelligence techniques to enhance the screening and diagnosis of PH. By developing AI-assisted programs, the study seeks to improve diagnostic accuracy compared to traditional methods. The ultimate goal is to facilitate earlier detection of PH, which is crucial for effective treatment.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have undergone the necessary routine examinations and right heart catheterization at Fuwai Hospital.
Not a fit: Patients who have not undergone right heart catheterization or whose examination results are of insufficient quality will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier and more accurate diagnoses of pulmonary hypertension, improving patient outcomes.
How similar studies have performed: While the use of artificial intelligence in medical diagnostics is a growing field, this specific application to pulmonary hypertension is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years old * Patients previously received chest X-ray, electrocardiography, echocardiography, other routine examinations, and RHC at the Fuwai Hospital, CAMS \& PUMC, Beijing, China Exclusion Criteria: * Patients without RHC * The quality of routine examinations and RHC cannot meet the requirement for further analysis * Severe loss of results of routine examinations (chest X-ray, electrocardiography, echocardiography, etc.)
Where this trial is running
Beijing, Beijing Municipality
- Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College — Beijing, Beijing Municipality, China (RECRUITING)
Study contacts
- Principal investigator: Zhihong Liu, MD, PhD — Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- Study coordinator: Zhihong Liu, MD, PhD
- Email: zhihongliufuwai@163.com
- Phone: 13269276067
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension, pulmonary hypertension, pulmonary vascular disease, right heart catheterization, echocardiography, electrocardiography, chest X-ray